FOR IMMEDIATE RELEASE

Jennerex and Lee's Pharm announces that its phase 2 study of Pexa-Vec in second-line advanced liver cancer did not meet its primary endpoint

-- Conducting additional analyses of data, continuing to advance clinical trials in kidney, colorectal, and ovarian cancers --

SAN FRANCISCO, [September 3 – 6pm CET, noon Eastern, 9am Pacific], 2013 — Jennerex Biotherapeutics and Lee's Pharm today announced that TRAVERSE, a randomized Phase 2b study of Pexa-Vec in second-line, advanced liver cancer patients had reached the pre-specified number of events for analysis. The study failed to meet its primary endpoint of overall survival for Pexa-Vec plus best supportive care (BSC) compared to BSC. Pexa-Vec was generally well tolerated with an adverse event profile consistent with previous Pexa-Vec studies in patients with advanced HCC. Additional analyses will be conducted to further understand these data.

"The rapid progression in this devastating and heterogeneous disease setting has been a longstanding challenge for developing new therapies in liver cancer," said Tony Reid, MD, PhD, TRAVERSE investigator and professor of clinical medicine, division of hematology-oncology, UC San Diego Moores Cancer Center. "Despite the disappointing outcome on the primary endpoint, the TRAVERSE study was well-conducted by Jennerex and no unexpected safety issues were observed. The field of oncolytic immunotherapy continues to have great promise for physicians and patients."

"Given the dearth of new treatments for patients with advanced liver cancer, we are disappointed with the results of the study. We will continue to advance our pipeline and look forward to data from Pexa-Vec Phase 2 studies in kidney, colorectal and ovarian cancer" said Laurent Fischer, MD, chairman and CEO of Jennerex. "Importantly, we want to thank the patients and their families as well as the investigators for participating in the study. We remain committed to developing new therapies to help patients with cancer."

"We will evaluate our China development strategy based on further analysis of the final results of Traverse along with studies in advanced HCC patients before end of 2013," said Dr. Benjamin Li, CEO of Lee's Pharmaceutical. "Given that primary liver cancer remains as one of the most common

and deadly malignancy in China, we believe that Pexa-Vec's potential in treatment of HCC should be further explored."

Pexa-Vec is also being investigated in phase 2 studies in colorectal, kidney and ovarian cancer. Jennerex will continue to advance the Pexa-Vec program in these indications while evaluating the Pexa-Vec liver cancer program.

The Jennerex pipeline also includes JX-929, an oncolytic immunotherapy in phase 1 clinical trials, and a platform for novel oncolytic and antibody-based immunotherapies.
The Lee's Pharmaceutical's oncology pipeline also includes cancer supporting products that are registration-enabling.

Pexa-Vec: A Multi-Mechanistic Approach To Targeting Cancer

Pexa-Vec is a proprietary, engineered oncolytic virus that is designed to selectively target and destroy cancer cells. Pexa-Vec is designed to attack cancer through three diverse mechanisms of action: 1) the lysis of cancer cells through viral replication, 2) the shutdown of the blood supply to tumors through vascular targeting and destruction, and 3) the stimulation of the body's immune response against cancer cells, i.e., active immunotherapy. Phase 1 and Phase 2 clinical trials in multiple cancer types to date have shown that Pexa-Vec, delivered either directly into tumors or systemically, induces tumor shrinkage and/or necrosis and is well-tolerated by patients (over 250 treated to date). Objective tumor responses have been demonstrated in a variety of cancers including liver, colon, kidney, lung cancer and melanoma. Pexa-Vec has had a favorable safety profile to date with predictable and generally mild side effects that typically include flu-like symptoms that resolve in 24 to 48 hours.

Pexa-Vec is the most advanced product candidate from Jennerex's proprietary SOLVE™ (Selective Oncolytic Vaccinia Engineering) platform. SOLVE takes advantage of the natural attributes of poxviruses as well as their ability to be genetically engineered to produce safe, therapeutic viruses that can infect solid tumors both systemically and locally. The vaccinia poxvirus strain backbone of Pexa-Vec has been used safely in millions of people as part of a worldwide vaccination program. This strain naturally targets cancer cells due to common genetic defects in cancer cells. Pexa-Vec was engineered to enhance this natural safety and cancer-selectivity by deleting its thymidine kinase (TK) gene, thus making it dependent on the cellular TK expressed at persistently high levels in cancer cells. To enhance product efficacy, Pexa-Vec is also engineered to express the immunogenic GM-CSF protein. GM-CSF complements the cancer cell lysis of the product candidate, leading to a cascade of events resulting in tumor necrosis, tumor vasculature shutdown and sustained anti-tumoral immune attack.

About Jennerex

Jennerex Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of groundbreaking oncolytic immunotherapies for patients with life-threatening cancers. The company's lead product candidate, Pexa-Vec (JX-594), is in mid-stage clinical development for the treatment of advanced primary liver cancer, colorectal cancer, kidney cancer and ovarian cancer, and its next generation product candidate, JX-929, is under investigation for a variety of other solid tumors. Jennerex is headquartered in San Francisco and has related research and development operations in Ottawa, Canada and South Korea. Pexa-Vec is partnered in Europe with Transgene, a member of the Institute Merieux group, in South Korea with Green Cross Corporation and in China with Lee's Pharmaceutical Holdings. For more information about Jennerex, please visit www.jennerex.com.

About Lee's Pharmaceutical Holdings Limited

Lee's Pharmaceutical Holdings Limited is a research-based biopharmaceutical company listed in Hong Kong with over 19 years operation in China's pharmaceutical industry. It is fully integrated with strong infrastructures in drug development, manufacturing, sales and marketing. It has established extensive partnership with over 20 international companies and currently has 14 products in the market place. Lee's focuses on several key disease areas such as cardiovascular, oncology, gynecology, dermatology and ophthalmology. Lee's development program is lauded with 30 products stemming from both internal R&D efforts and collaborations with US, European and Japanese companies and aspiring to combat diseases such as liver cancer and pulmonary hypertension. The mission of Lee's is to become a successful biopharmaceutical group in Asia providing innovative products to fight diseases and improve health and quality of life. Additional information about Lee's Pharmaceutical is available at www.leespharm.com.

Safe Harbor Statement

The performance and the results of operation of Lee's during the past years are historical in nature and past performance can be no guarantee of future results of the Lee's. This news release may contain forward-looking statements and opinions that involve risks and uncertainties. Actual results may differ materially from expectations discussed in such forward-looking statements and opinions. Neither Lee's nor the Directors, employees or agents of Lee's assume (a) any obligation to correct or update the forward-looking statements or opinions contained in this news release; and (b) any liability in the event that any of the forward-looking statements or opinions does not materialise or turns out to be incorrect.

Contact:
Katherine Stueland
kstueland@jennerex.com

Vivian Fung
Tel: (852)2314-1282
Fax: (852)2314-1708
info@leespharm.com